On this page · 8 sections
Prescription only OTC eye drop

Brytly

Generic name: apraclonidine ophthalmic 0.125%

Last updated October 21, 2026 0 views Reviewed by Carmen Pope, Senior Medical Editor, B. Pharm
Share

What is Brytly?

Brytly is an over-the-counter eye drop used to relieve eye redness caused by minor eye irritations in adults and children 12 years of age and over.

Brytly (apraclonidine ophthalmic 0.125%) is an alpha-adrenergic agonist, a type of medicine that narrows blood vessels. When the white of the eye looks red, it is usually because small blood vessels on the surface of the eye have widened. Brytly works by narrowing these widened blood vessels, which reduces the look of redness. It is used as 1 drop in the affected eye every 12 hours, and no more than 2 times a day.

Brytly was approved by the FDA on October 16, 2026, under NDA 220341, and is the first nonprescription (over-the-counter) eye drop to contain apraclonidine. It is distributed by Alcon.

Warnings

For external use only.

Do not use Brytly:

  • if you are sensitive to any ingredient in this product
  • if the solution changes color or becomes cloudy

Stop use and ask a doctor if:

  • you experience eye pain or changes in vision
  • you have continued redness or irritation of the eye
  • your eye condition lasts more than 3 days or gets worse

If you are pregnant or breastfeeding, ask a health professional before use.

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

Side Effects

Common side effects

The most common side effects of Brytly are usually mild and temporary. They may include:

  • eye stinging, burning, or itching when the drops are applied
  • a feeling that something is in your eye
  • mild, temporary blurred vision
  • dry eyes
  • red or swollen eyelids, watery eyes, or tearing
  • dry mouth.

Less common side effects

Apraclonidine can be absorbed into the body in small amounts. Less commonly, it may cause:

  • dizziness, headache, or drowsiness
  • changes in heart rate or blood pressure.

Serious side effects and warnings

Stop using Brytly and ask a doctor if you have:

  • eye pain or changes in vision
  • continued redness or irritation of the eye
  • redness that lasts more than 3 days or gets worse
  • severe itching, redness, or discomfort in or around the eye
  • crusting or drainage around the eye

Get emergency medical help if you have signs of an allergic reaction, such as hives; difficulty breathing; swelling of your face, lips, tongue, or throat; or a rash, swelling, or increased itching around the eye or eyelids.

How to use Brytly

Adults and children 12 years of age and over:

  • Instill 1 drop in the affected eye or eyes every 12 hours.
  • Do not use more than 2 times daily.
  • Remove contact lenses before use. Wait at least 10 minutes before putting your contact lenses back in.
  • If you are using other eye drops, wait at least 5 minutes between each product.
  • To avoid contamination, do not touch the tip of the container to any surface.
  • Replace the cap after each use.

Children under 12 years of age: Do not use.

  • Do not touch the tip of the container to your eye or any other surface, as this can contaminate the drops.
  • Do not use the drops if the solution has changed color or become cloudy.
  • Do not use more than 2 times a day.
  • Remove contact lenses before use and wait at least 10 minutes before putting them back in.

What other drugs will affect Brytly

The Brytly Drug Facts label does not list specific drug interactions. If you take other medicines or use other eye drops, ask a doctor or pharmacist before use. When using more than one eye drop, wait at least 5 minutes between each product.

Monoamine oxidase (MAO) inhibitors: The prescribing information for the prescription form of apraclonidine states that it should not be used by people who have taken an MAO inhibitor within the past 14 days, because a dangerous interaction could occur. The Brytly over-the-counter label does not include this warning, but consumers who take or have recently taken an MAO inhibitor should be aware of it and ask a doctor or pharmacist before using Brytly. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, and tranylcypromine.

Storage

Store at 36 degrees F to 77 degrees F (2 degrees C to 25 degrees C). Keep the bottle tightly closed and replace the cap after each use.

Ingredients

Active ingredient: apraclonidine 0.125% (equivalent to apraclonidine hydrochloride 0.144%), a redness reliever.

Inactive ingredients: benzalkonium chloride, citric acid (monohydrate), hypromellose 2910, purified water, sodium chloride, and sodium citrate (dihydrate). Hydrochloric acid and sodium hydroxide may be used to adjust pH.

Frequently asked questions

What is Brytly used for?
Brytly is an over-the-counter eye drop used to relieve eye redness caused by minor eye irritations in adults and children 12 years of age and over. It contains apraclonidine 0.125%, which reduces redness by narrowing the widened blood vessels on the surface of the eye.
When was Brytly approved by the FDA?
The FDA approved Brytly on October 16, 2026, as a nonprescription (over-the-counter) eye drop. It is the first nonprescription eye drop to contain apraclonidine. Higher-strength apraclonidine eye drops remain available only by prescription.
What is the difference between over-the-counter Brytly and prescription Iopidine?
Brytly and Iopidine contain the same active ingredient, apraclonidine, but they differ in strength and in what they treat. Brytly is a lower strength, 0.125%, and is sold over the counter to relieve redness from minor eye irritation. Iopidine is prescription only and comes in higher strengths, 0.5% and 1%. It is used to control or prevent high pressure inside the eye, for example, during glaucoma treatment or around certain laser eye surgeries. Because Iopidine is much stronger and treats a different, more serious condition, it is used only under a doctor's care. The lower 0.125% strength in Brytly is intended only for the temporary relief of eye redness.
Is Brytly the same as Lumify?
No. Brytly and Lumify are both over-the-counter redness-reliever eye drops in the same general drug class (alpha-adrenergic agonists), but they contain different active ingredients. Brytly contains apraclonidine 0.125%, while Lumify contains brimonidine tartrate 0.025%.
Can I use Brytly if I wear contact lenses?
Remove your contact lenses before using Brytly. Wait at least 10 minutes after using the drops before putting your lenses back in.
How often and how long can I use Brytly?
Use 1 drop in the affected eye or eyes every 12 hours, and no more than 2 times a day. Stop use and ask a doctor if your eye redness or irritation lasts more than 3 days or gets worse.
Can I use Brytly if I take an MAO inhibitor?
Ask a doctor or pharmacist first. The prescribing information for prescription apraclonidine says it should not be used by people who have taken an MAO inhibitor within the past 14 days. Although this warning is not printed on the Brytly over-the-counter label, it is safest to check with a healthcare professional before use if you take or have recently taken an MAO inhibitor.
Does Brytly cause rebound redness?
The Brytly label does not provide information about rebound redness, which is redness that returns or worsens with overuse. To lower this risk, do not use more than directed, and stop use and ask a doctor if your redness lasts more than 3 days or gets worse. Brytly is distributed by Alcon. The FDA granted the nonprescription approval to Alcon on October 16, 2026.
Before you take this medicine: the information on this page is general and may not cover your personal circumstances. Read the label supplied with your medicine and ask a pharmacist or doctor if you are unsure, especially if you are pregnant, breastfeeding, taking other medicines or managing a long-term condition.
General medicine information Consumer-friendly language Source: Drugs.com

Content is provided for education and is not medical advice. See our medical disclaimer. Source page medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm on October 21, 2026.